Literature DB >> 10997973

Quality of life in 244 recipients of allogeneic bone marrow transplantation.

S Chiodi1, S Spinelli, G Ravera, A R Petti, M T Van Lint, T Lamparelli, F Gualandi, D Occhini, N Mordini, G Berisso, S Bregante, F Frassoni, A Bacigalupo.   

Abstract

The number of long-term survivors after allogeneic bone marrow transplantation (BMT) has been increasing over the past years, and quality of life (QOL) has become an important end-point. We studied 244 patients undergoing an allogeneic BMT to identify factors and events influencing psychosocial outcome. Patients enrolled received the Psychosocial Adjustment to Illness Scale (PAIS) questionnaire assessing psychological and social adjustment to chronic illness or its sequelae. Eighty-two per cent of patients had a haematological disease. The median age was 28 years at BMT, and the median follow-up was 61 months. The median overall PAIS score for all patients was 56 (range 22-76): 25% (n = 61) of patients were considered to have a good QOL (</= 25 percentile score); 44% (n = 108) of patients had an intermediate QOL (26-75 percentile score) and 31% (n = 75) had a poor QOL (> 75 percentile score). Factors associated with a poor QOL in multivariate analysis were: patients' age at BMT (> 25 years, P < 0.01); presence of long-term sequelae (P < 0.01); chronic graft-versus-host disease (GVHD) (P < 0.05); and a short interval from BMT (< 5 years; P < 0.05). The QOL improved with time: 12% of patients reported a good QOL within 5 years compared with 38% after this time point and, conversely, 38% reported a poor QOL within 5 years compared with 24% after this time point (P < 0. 0001). Older patients had significantly poorer QOL compared with younger patients (< or = 25 years; P = 0.01). Females had significantly poorer scores when compared with males in the sexual (P < 0.0001) and psychological domains (P = 0.001). The data suggest that (i) one-third of patients undergoing allogeneic BMT report a poor QOL; (ii) factors associated with poor QOL are older age, presence of long-term sequelae, chronic GVHD and short follow-up; (iii) QOL is superior in long-term survivors; and (iv) BMT affects different aspects of life in males and females. A longitudinal study is ongoing to prove the effect of time on quality of life.

Entities:  

Mesh:

Year:  2000        PMID: 10997973     DOI: 10.1046/j.1365-2141.2000.02053.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  51 in total

1.  Preliminary psychometric evaluation of the Child Health Ratings Inventory (CHRIs) and Disease-Specific Impairment Inventory-Hematopoietic Stem Cell Transplantation (DSII-HSCT) in parents and children.

Authors:  S K Parsons; M C Shih; D K Mayer; S E Barlow; S E Supran; S L Levy; S Greenfield; S H Kaplan
Journal:  Qual Life Res       Date:  2005-08       Impact factor: 4.147

2.  Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study.

Authors:  Christopher J Fraser; Smita Bhatia; Kirsten Ness; Andrea Carter; Liton Francisco; Mukta Arora; Pablo Parker; Stephen Forman; Daniel Weisdorf; James G Gurney; K Scott Baker
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

3.  Late congestive heart failure after hematopoietic cell transplantation.

Authors:  Saro H Armenian; Can-Lan Sun; Liton Francisco; Julia Steinberger; Seira Kurian; F Lennie Wong; Jon Sharp; Richard Sposto; Stephen J Forman; Smita Bhatia
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

4.  Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS).

Authors:  Can-Lan Sun; Liton Francisco; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

5.  Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD.

Authors:  F L Dignan; S Aguilar; J J Scarisbrick; B E Shaw; M N Potter; J Cavenagh; J F Apperley; A K Fielding; A Pagliuca; K Raj; D I Marks; A Peniket; C Crawley; M B Koh; F J Child
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

6.  Fatigue predicts impaired social adjustment in survivors of allogeneic hematopoietic cell transplantation (HCT).

Authors:  Jumin Park; Leslie Wehrlen; Sandra A Mitchell; Li Yang; Margaret F Bevans
Journal:  Support Care Cancer       Date:  2018-08-22       Impact factor: 3.603

7.  Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.

Authors:  Areej El-Jawahri; Joseph Pidala; Yoshi Inamoto; Xiaoyu Chai; Nandita Khera; William A Wood; Corey Cutler; Mukta Arora; Paul A Carpenter; Jeanne Palmer; Mary Flowers; Daniel Weisdorf; Steven Pavletic; Samantha Jaglowski; Madan Jagasia; Stephanie J Lee; Yi-Bin Chen
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-09       Impact factor: 5.742

8.  Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns.

Authors:  F Lennie Wong; Liton Francisco; Kayo Togawa; Alysia Bosworth; Mitzi Gonzales; Cara Hanby; Melanie Sabado; Marcia Grant; Stephen J Forman; Smita Bhatia
Journal:  Blood       Date:  2010-01-20       Impact factor: 22.113

9.  Child and parental adaptation to pediatric stem cell transplantation.

Authors:  C M Jantien Vrijmoet-Wiersma; Annemarie M Kolk; Martha A Grootenhuis; Emmelien M Spek; Jeanine M M van Klink; R Maarten Egeler; Robbert G M Bredius; Hendrik M Koopman
Journal:  Support Care Cancer       Date:  2008-12-03       Impact factor: 3.603

10.  A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.

Authors:  Pattara Leelahavarong; Usa Chaikledkaew; Suradej Hongeng; Vijj Kasemsup; Yoel Lubell; Yot Teerawattananon
Journal:  BMC Health Serv Res       Date:  2010-07-16       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.